{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:33:27Z","timestamp":1787506407525,"version":"build-2736575974"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008349","name":"University of Duisburg-Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Symptomatic epilepsy is a common symptom of glioblastoma, which may occur in different stages of disease. There are discrepant reports on association between early seizures and glioblastoma survival, even less is known about the background of these seizures. We aimed at analyzing the risk factors and clinical impact of perioperative seizures in glioblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All consecutive cases with de-novo glioblastoma treated at our institution between 01\/2006 and 12\/2018 were eligible for this study. Perioperative seizures were stratified into seizures at onset (SAO) and early postoperative seizures (EPS, \u226421days after surgery). Associations between patients characteristics and overall survival (OS) with SAO and EPS were addressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the final cohort (n = 867), SAO and EPS occurred in 236 (27.2%) and 67 (7.7%) patients, respectively. SAO were independently predicted by younger age (P = .009), higher KPS score (P = .002), tumor location (parietal lobe, P = .001), GFAP expression (\u226535%, P = .045), and serum chloride at admission (&amp;gt;102 mmol\/L, P = .004). In turn, EPS were independently associated with tumor location (frontal or temporal lobe, P = .013) and pathologic laboratory values at admission (hemoglobin &amp;lt; 12 g\/dL, [P = .044], CRP &amp;gt; 1.0 mg\/dL [P = 0.036], and GGT &amp;gt; 55 U\/L [P = 0.025]). Finally, SAO were associated with gross-total resection (P = .006) and longer OS (P = .030), whereas EPS were related to incomplete resection (P = .005) and poorer OS (P = .009).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In glioblastoma patients, SAO and EPS seem to have quite different triggers and contrary impact on treatment success and OS. The clinical characteristics of SAO and EPS patients might contribute to the observed survival differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaa158","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T10:28:12Z","timestamp":1605695292000},"source":"Crossref","is-referenced-by-count":12,"title":["Preoperative and early postoperative seizures in patients with glioblastoma\u2014two sides of the same coin?"],"prefix":"10.1093","volume":"3","author":[{"given":"Yahya","family":"Ahmadipour","sequence":"first","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laur\u00e8l","family":"Rauschenbach","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"},{"name":"DKFZ-Division Translational Neurooncology at the WTZ, German Cancer Research Center (DKFZ) Heidelberg and German Cancer Consortium (DKTK) Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-5024","authenticated-orcid":false,"given":"Marvin","family":"Darkwah Oppong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Lazaridis","sequence":"additional","affiliation":[{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"},{"name":"Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, Essen, Germany"},{"name":"Department for Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M","family":"Quesada","sequence":"additional","affiliation":[{"name":"Department for Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Junker","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pierscianek","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dammann","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten H","family":"Wrede","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Scheffler","sequence":"additional","affiliation":[{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"},{"name":"DKFZ-Division Translational Neurooncology at the WTZ, German Cancer Research Center (DKFZ) Heidelberg and German Cancer Consortium (DKTK) Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"},{"name":"Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, Essen, Germany"},{"name":"Department for Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"},{"name":"Department of Radiotherapy, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sure","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8356-6629","authenticated-orcid":false,"given":"Ramazan","family":"Jabbarli","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"issue":"4","key":"2021012805161802200_CIT0001","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.pjnns.2018.06.001","article-title":"Brain tumor related-epilepsy","volume":"52","author":"Goldstein","year":"2018","journal-title":"Neurol Neurochir Pol."},{"key":"2021012805161802200_CIT0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clineuro.2017.11.015","article-title":"Quantifying the prognostic significance in glioblastoma of seizure history at initial presentation: a systematic review and meta-analysis","volume":"164","author":"Lu","year":"2018","journal-title":"Clin Neurol Neurosurg."},{"issue":"7","key":"2021012805161802200_CIT0003","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1634\/theoncologist.2014-0060","article-title":"Seizure prognosis in brain tumors: new insights and evidence-based management","volume":"19","author":"Vecht","year":"2014","journal-title":"Oncologist."},{"issue":"5","key":"2021012805161802200_CIT0004","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/neuros\/nyx084","article-title":"Improved survival with decreased wait time to surgery in glioblastoma patients presenting with seizure","volume":"81","author":"Flanigan","year":"2017","journal-title":"Neurosurgery."},{"issue":"11","key":"2021012805161802200_CIT0005","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.clon.2017.05.010","article-title":"Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes","volume":"29","author":"Lorimer","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2021012805161802200_CIT0006","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clineuro.2015.10.002","article-title":"Prognostic implications of epilepsy in glioblastomas","volume":"139","author":"Toledo","year":"2015","journal-title":"Clin Neurol Neurosurg."},{"issue":"7","key":"2021012805161802200_CIT0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jocn.2005.10.011","article-title":"Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables","volume":"13","author":"Yuile","year":"2006","journal-title":"J Clin Neurosci."},{"issue":"5","key":"2021012805161802200_CIT0008","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/neuonc\/nov238","article-title":"Prognostic relevance of epilepsy at presentation in glioblastoma patients","volume":"18","author":"Berendsen","year":"2016","journal-title":"Neuro Oncol."},{"issue":"3","key":"2021012805161802200_CIT0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2176\/nmc.oa.2017-0167","article-title":"Prognostic factors in glioblastoma: is there a role for epilepsy?","volume":"58","author":"Dobran","year":"2018","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"1","key":"2021012805161802200_CIT0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/epi.14615","article-title":"Seizures as presenting symptom in patients with glioblastoma","volume":"60","author":"D\u00fchrsen","year":"2019","journal-title":"Epilepsia."},{"issue":"4","key":"2021012805161802200_CIT0011","doi-asserted-by":"crossref","first-page":"E722","DOI":"10.1093\/neuros\/nyz079","article-title":"Association between tumor compartment volumes, the incidence of pretreatment seizures, and statin-mediated protective effects in glioblastoma","volume":"85","author":"Henker","year":"2019","journal-title":"Neurosurgery."},{"issue":"15","key":"2021012805161802200_CIT0012","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.0b013e3181bbfeca","article-title":"Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma","volume":"73","author":"Jaeckle","year":"2009","journal-title":"Neurology."},{"issue":"7","key":"2021012805161802200_CIT0013","doi-asserted-by":"crossref","first-page":"e0158206","DOI":"10.1371\/journal.pone.0158206","article-title":"Epilepsy in adults with supratentorial glioblastoma: incidence and influence factors and prophylaxis in 184 patients","volume":"11","author":"Liang","year":"2016","journal-title":"PLoS One."},{"issue":"3","key":"2021012805161802200_CIT0014","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00701-006-1092-y","article-title":"Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients","volume":"149","author":"Mineo","year":"2007","journal-title":"Acta Neurochir (Wien)"},{"issue":"5","key":"2021012805161802200_CIT0015","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/neuonc\/nos338","article-title":"Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme","volume":"15","author":"Rosati","year":"2013","journal-title":"Neuro Oncol."},{"issue":"7","key":"2021012805161802200_CIT0016","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/1049909116647405","article-title":"Incidence, characteristics, and implications of seizures in patients with Glioblastoma","volume":"34","author":"Shin","year":"2017","journal-title":"Am J Hosp Palliat Care."},{"issue":"2","key":"2021012805161802200_CIT0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/brainsci10020091","article-title":"Retrospective and randomized analysis of influence and correlation of clinical and molecular prognostic factors in a mono-operative series of 122 patients with glioblastoma treated with STR or GTR","volume":"10","author":"Salvati","year":"2020","journal-title":"Brain Sci"},{"issue":"3","key":"2021012805161802200_CIT0018","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"7","key":"2021012805161802200_CIT0019","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol."},{"issue":"12","key":"2021012805161802200_CIT0020","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology."},{"issue":"17","key":"2021012805161802200_CIT0021","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/cncr.29439","article-title":"Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer."},{"issue":"3","key":"2021012805161802200_CIT0022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11060-016-2191-0","article-title":"Does the choice of antiepileptic drug affect survival in glioblastoma patients?","volume":"129","author":"Knudsen-Baas","year":"2016","journal-title":"J Neurooncol."},{"key":"2021012805161802200_CIT0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jns.2018.04.004","article-title":"Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: retrospective multicentre study in 285 Italian patients","volume":"390","author":"Rigamonti","year":"2018","journal-title":"J Neurol Sci."},{"issue":"3","key":"2021012805161802200_CIT0024","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/02688697.2011.638996","article-title":"Effect of valproic acid on the outcome of glioblastoma multiforme","volume":"26","author":"Tsai","year":"2012","journal-title":"Br J Neurosurg."},{"issue":"7","key":"2021012805161802200_CIT0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? a pooled analysis of prospective clinical trials in newly diagnosed Glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J Clin Oncol."},{"key":"2021012805161802200_CIT0026","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.seizure.2019.05.018","article-title":"Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control","volume":"69","author":"Feyissa","year":"2019","journal-title":"Seizure."},{"issue":"1","key":"2021012805161802200_CIT0027","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0959-8049(97)00374-2","article-title":"Prevalence and prognostic significance of epilepsy in patients with gliomas","volume":"34","author":"Lote","year":"1998","journal-title":"Eur J Cancer."},{"issue":"10","key":"2021012805161802200_CIT0028","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"12","key":"2021012805161802200_CIT0029","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.4065\/79.12.1489","article-title":"Seizure prophylaxis in patients with brain tumors: a meta-analysis","volume":"79","author":"Sirven","year":"2004","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"2021012805161802200_CIT0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.neuchi.2019.12.012","article-title":"Does the expression of glial fibrillary acid protein (GFAP) stain in glioblastoma tissue have a prognostic impact on survival?","volume":"66","author":"Ahmadipour","year":"2020","journal-title":"Neurochirurgie"},{"issue":"6","key":"2021012805161802200_CIT0031","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2021012805161802200_CIT0032","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","article-title":"Tumor-related epilepsy: epidemiology, pathogenesis and management","volume":"139","author":"Chen","year":"2018","journal-title":"J Neurooncol."},{"issue":"2","key":"2021012805161802200_CIT0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/157015912800604470","article-title":"Brain tumor-related epilepsy","volume":"10","author":"Maschio","year":"2012","journal-title":"Curr Neuropharmacol."},{"key":"2021012805161802200_CIT0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.12.013","article-title":"Epileptic features and survival in glioblastomas presenting with seizures","volume":"130","author":"Toledo","year":"2017","journal-title":"Epilepsy Res."},{"issue":"1","key":"2021012805161802200_CIT0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/1744-1633.12102","article-title":"Risk factors for seizures and antiepileptic drug-associated adverse effects in high-grade glioma patients: A multicentre, retrospective study in Hong Kong","volume":"19","author":"Woo","year":"2015","journal-title":"Surg Pract."},{"key":"2021012805161802200_CIT0036","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2016.12.012","article-title":"Epilepsy-related brain tumors","volume":"44","author":"Ert\u00fcrk \u00c7etin","year":"2017","journal-title":"Seizure."},{"key":"2021012805161802200_CIT0037","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12437","article-title":"Seizure characteristics and prognostic factors of gliomas","volume":"54","author":"Kerkhof","year":"2013","journal-title":"Epilepsia."},{"issue":"4","key":"2021012805161802200_CIT0038","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/00207454.2011.639470","article-title":"Human intravenous immunoglobulins suppress seizure activities and inhibit the activation of GFAP-positive astrocytes in the hippocampus of picrotoxin-kindled rats","volume":"122","author":"Li","year":"2012","journal-title":"Int J Neurosci."},{"key":"2021012805161802200_CIT0039","doi-asserted-by":"crossref","first-page":"134518","DOI":"10.1016\/j.neulet.2019.134518","article-title":"Relationships between astrocytes and absence epilepsy in rat: an experimental study","volume":"712","author":"\u00c7avdar","year":"2019","journal-title":"Neurosci Lett."},{"issue":"3","key":"2021012805161802200_CIT0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.seizure.2011.12.016","article-title":"The pathogenesis of tumor-related epilepsy and its implications for clinical treatment","volume":"21","author":"You","year":"2012","journal-title":"Seizure."},{"key":"2021012805161802200_CIT0041","first-page":"197","article-title":"Seizures and the regulation of astroglial gene expression","volume":"7","author":"Steward","year":"1992","journal-title":"Epilepsy Res Suppl."},{"issue":"3","key":"2021012805161802200_CIT0042","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3171\/jns.1997.87.3.0420","article-title":"Role of glial filaments in cells and tumors of glial origin: a review","volume":"87","author":"Rutka","year":"1997","journal-title":"J Neurosurg."},{"issue":"12","key":"2021012805161802200_CIT0043","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1528-1167.2006.00861.x","article-title":"Electrolytes disturbances and seizures","volume":"47","author":"Castilla-Guerra","year":"2006","journal-title":"Epilepsia."},{"issue":"1","key":"2021012805161802200_CIT0044","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3988\/jcn.2016.12.1.21","article-title":"Acute symptomatic seizures caused by electrolyte disturbances","volume":"12","author":"Nardone","year":"2016","journal-title":"J Clin Neurol."},{"key":"2021012805161802200_CIT0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fncel.2015.00419","article-title":"Ion dynamics during seizures","volume":"9","author":"Raimondo","year":"2015","journal-title":"Front Cell Neurosci."},{"key":"2021012805161802200_CIT0046","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eplepsyres.2016.07.010","article-title":"Compromised GABAergic inhibition contributes to tumor-associated epilepsy","volume":"126","author":"MacKenzie","year":"2016","journal-title":"Epilepsy Res."},{"issue":"244","key":"2021012805161802200_CIT0047","doi-asserted-by":"crossref","first-page":"244ra289","DOI":"10.1126\/scitranslmed.3008065","article-title":"Cortical GABAergic excitation contributes to epileptic activities around human glioma","volume":"6","author":"Pallud","year":"2014","journal-title":"Science Translational Medicine"},{"key":"2021012805161802200_CIT0048","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/9781118414019.ch6","article-title":"Seizures due to systemic disease","volume-title":"Neurological Disorders Due to Systemic Disease","author":"Hoerth","year":"2013"},{"key":"2021012805161802200_CIT0049","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.wneu.2017.05.028","article-title":"Risk factors for preoperative seizures and loss of seizure control in patients undergoing surgery for metastatic brain tumors","volume":"104","author":"Wu","year":"2017","journal-title":"World Neurosurg."},{"issue":"2","key":"2021012805161802200_CIT0050","doi-asserted-by":"crossref","first-page":"e0211644","DOI":"10.1371\/journal.pone.0211644","article-title":"AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro","volume":"14","author":"Lange","year":"2019","journal-title":"PLoS One."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaa158\/34383170\/vdaa158.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdaa158\/36126045\/vdaa158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdaa158\/36126045\/vdaa158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:26:38Z","timestamp":1697113598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaa158\/5989005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaa158","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,11,18]]},"article-number":"vdaa158"}}